- Private equity firm TPG Capital prepares to exit from its $1.9B buyout of Par Pharmaceutical Holdings (NYSE:PRX) in 2012 with the filing of an S-1 for a $100M IPO.
- The company sells a portfolio of 95 high-barrier-to-entry generic drugs that are characterized by being more difficult to formulate and manufacture or face complex legal or regulatory challenges. It operates in two business segments: Par Pharmaceutical, which sells the generic line and Par Specialty Pharmaceuticals, which sells two branded products.
- 2014 Financial Performance ($M): Total Revenues: 1,308.9 (+19.2%); Net Product Sales: 1,278.1 (+20.3%); Gross Margin: 479.1 (+50.7%); Gross Margin: 36.6% (+26.2%); Operating Expenses: 542.7 (+41.5%); Net Loss: (105.5) (+0.4%); Loss Per Share: (0.14) (+6.7%); CF Ops: 145.2 (+28.5%); Non-GAAP EBITDA: 433.8 (+41.3%).
Private equity firm prepares for exit with Par Pharma IPO
Recommended For You
More Trending News
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
PRX | - | - |
Par Pharmaceutical Companies, Inc. |